Evotec
Ernesto Felix Diaz Parga, PhD, currently serves as a research scientist and bioinformatician in proteomics at Evotec since February 2023 and as a scientific collaborator at European University Cyprus, delivering medical microbiology lectures to second-year medical students. Previously, Ernesto held the position of technical lead in genomic sequencing at Cignpost Diagnostics and served in multiple roles, including data team lead, data scientist, bioscientist lead, and laboratory scientist at Medicines Discovery Catapult. Ernesto completed a PhD in Molecular Medicine at The University of Sheffield, focusing on the acetylome of Neisseria gonorrhoeae, and holds an MS in Molecular Medicine from the same institution. Additional experience includes quality control management for laboratory accreditation at entidad mexicana de acreditación, a.c., and undergraduate research at Children’s Hospital of Mexico. Educational background includes a bachelor’s degree in microbiology from Instituto Politécnico Nacional and an exchange program at Nanyang Technological University Singapore.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.